Children’s positive responses to SSRI antidepressant treatments for depression are even less significant than adult responses, and drop to “minimal” after just four weeks, according to a meta-analysis published in the Journal of the American Academy of Child & Adolescent Psychiatry.
University of Vermont-led researchers conducted a meta-analysis of randomized controlled trials comparing placebo and SSRI antidepressants for major depressive disorder (MDD) in children, including 13 trials with a total of 3,004 patients.
“SSRIs were demonstrated to have a smaller benefit in pediatric compared to adult MDD,” they concluded. “Treatment gains in pediatric MDD are greatest early in treatment and are on average minimal after 4 weeks of SSRI pharmacotherapy in pediatric MDD.”
1 Boring Old Man noted that the study found there were no differences with dosage levels or different SSRIs, and commented, “In light of the findings of the much lower efficacy of these drugs in adolescents it seems ludicrous to have the same guidelines for both adults and children given its near inertness in the latter.”
Varigonda, Anjali L., Ewgeni Jakubovski, Matthew J. Taylor, Nick Freemantle, Catherine Coughlin, and Michael H. Bloch. “Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder.” Journal of the American Academy of Child & Adolescent Psychiatry. Accessed May 24, 2015. doi:10.1016/j.jaac.2015.05.004. (Abstract)
a study worth looking into… (1 Boring Old Man, May 27, 2015)